discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Search
Hannah Bussmann
Hannah Bussmann speaks about working in Global Internal Investigations as part of corporate legal and compliance at Boehringer Ingelheim.
Nadine Becker
Nadine Becker, speaks about her role in the Master Data Management and her 20 year career in Boehringer Ingelheim.
Stefanie Bock Kreilinger
Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
Shannon Rountos
Shannon Rountos, Head of Newsroom within Corporate Affairs, speaks about her rewarding and fulfilling career in Boehringer Ingelheim.
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
Maria Wlaschitz
Eva-Maria Wlaschitz, a development scientist at Boehringer Ingelheim in Vienna, Austria, speaks about the numerous growth opportunities.
Cooperation with The Defeat-NCD Partnership
Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Marie Penzold
Marie Penzold talks about her career as a HR business partner in the Innovation unit here at Boehringer Ingelheim.
FuturePack
Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Simon Heinrich
Simon Heinrich, an automation engineer in the Engineering and Facilities department, provides an in-depth look at working life at Boehringer Ingelheim.
Jan-Erik Schafer
Jan Erik, Senior Team Leader in the upstream pharmaceutical production talks about his motivating and fun career at Boehringer Ingelheim.
Brightline-1 trial launch in rare sarcoma
Mehdi Lahmar discusses “Brightline-1”, and our commitment to patients with Dedifferentiated Liposarcoma (DDLPS).
collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Ryan Henri Rickards
Ryan Henry Rickards, a senior finance manager for US Animal Health Commercial Controlling team, highlights his career at Boehringer Ingelheim.
Nelli Milosch
Nelli Milosch, a team lead for our field-based medical team in Germany, says that the people is the best thing about working in Boehringer Ingelheim.
Boehringer Ingelheim Access to Healthcare Strategy last mile
We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
Global Top Employer 2023
Global Top Employer 2023
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
World Rabies Day 2020 sustainable dog vaccination
World Rabies Day 2020 sustainable dog vaccination
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Animal Health Collaboration with Novozymes
Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f
Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund